ArticleJCI insight2025

MUC1-C dependence in treatment-resistant prostate cancer uncovers a target for antibody-drug conjugate therapy.

Keisuke Shigeta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.